دنبال کردن
Hugo M. Vargas
Hugo M. Vargas
Executive Director, Translational Safety & Pharmacology, Amgen, Inc
ایمیل تأیید شده در amgen.com
عنوان
نقل شده توسط
نقل شده توسط
سال
Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
GM Bores, FP Huger, W Petko, AE Mutlib, F Camacho, DK Rush, DE Selk, ...
The Journal of pharmacology and experimental therapeutics 277 (2), 728-738, 1996
3681996
Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
MJ Forrest, D Bloomfield, RJ Briscoe, PN Brown, AM Cumiskey, J Ehrhart, ...
British journal of pharmacology 154 (7), 1465-1473, 2008
3352008
Discovery of Potent 3,5-Diphenyl-1,2,4-oxadiazole Sphingosine-1-phosphate-1 (S1P1) Receptor Agonists with Exceptional Selectivity against S1P2 and S1P3
Z Li, W Chen, JJ Hale, CL Lynch, SG Mills, R Hajdu, CA Keohane, ...
Journal of Medicinal Chemistry 48 (20), 6169-6173, 2005
1572005
Design, Synthesis, and Evaluation of a Novel 4-Aminomethyl-4-fluoropiperidine as a T-Type Ca2+ Channel Antagonist
WD Shipe, JC Barrow, ZQ Yang, CW Lindsley, FV Yang, KAS Schlegel, ...
Journal of medicinal chemistry 51 (13), 3692-3695, 2008
1442008
Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative
JP Piccini, DJ Whellan, BR Berridge, JK Finkle, SD Pettit, N Stockbridge, ...
American heart journal 158 (3), 317-326, 2009
1422009
Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics
HM Vargas, AS Bass, A Breidenbach, HS Feldman, GA Gintant, ...
Journal of pharmacological and toxicological methods 58 (2), 72-76, 2008
1162008
Comparison of the inhibitory potencies of N (G)-methyl-, N (G)-nitro-and N (G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release.
HM Vargas, JM Cuevas, LJ Ignarro, G Chaudhuri
The Journal of pharmacology and experimental therapeutics 257 (3), 1208-1215, 1991
1101991
Phenyl-substituted analogs of oxotremorine as muscarinic antagonists
BM Nilsson, HM Vargas, B Ringdahl, U Hacksell
Journal of medicinal chemistry 35 (2), 285-294, 1992
1031992
Discovery of 1, 4-substituted piperidines as potent and selective inhibitors of T-type calcium channels
ZQ Yang, JC Barrow, WD Shipe, KAS Schlegel, Y Shu, FV Yang, ...
Journal of medicinal chemistry 51 (20), 6471-6477, 2008
1022008
Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure
HM Vargas, AJ Gorman
Life sciences 57 (25), 2291-2308, 1995
951995
Proarrhythmia risk assessment in human induced pluripotent stem cell-derived cardiomyocytes using the maestro MEA platform
Y Qu, HM Vargas
Toxicological Sciences 147 (1), 286-295, 2015
892015
The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative
L Ewart, M Aylott, M Deurinck, M Engwall, DJ Gallacher, H Geys, P Jarvis, ...
Toxicological Sciences 142 (2), 427-435, 2014
812014
Time for a fully integrated nonclinical–clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective
HM Vargas, MG Rolf, TA Wisialowski, W Achanzar, A Bahinski, A Bass, ...
Clinical Pharmacology & Therapeutics 109 (2), 310-318, 2021
762021
Safety pharmacology investigations on the nervous system: An industry survey
S Authier, J Arezzo, MS Delatte, MJ Kallman, C Markgraf, D Paquette, ...
Journal of pharmacological and toxicological methods 81, 37-46, 2016
752016
Physiological release of nitric oxide is dependent on the level of vascular tone
HM Vargas, LJ Ignarro, G Chaudhuri
European journal of pharmacology 190 (3), 393-397, 1990
751990
Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5
VJ Cee, M Frohn, BA Lanman, J Golden, K Muller, S Neira, A Pickrell, ...
ACS Medicinal Chemistry Letters 2 (2), 107-112, 2011
652011
Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials
AN Mead, HR Amouzadeh, K Chapman, L Ewart, A Giarola, SJ Jackson, ...
Regulatory Toxicology and Pharmacology 80, 348-357, 2016
612016
Assessment of two external telemetry systems (PhysioJacket™ and JET™) in beagle dogs with telemetry implants
RW Chui, A Fosdick, J Jiang, BA Bruenner, HM Vargas
Journal of Pharmacological and Toxicological Methods 60 (1), 58-68, 2009
562009
Evaluation of drug‐induced QT interval prolongation in animal and human studies: a literature review of concordance
HM Vargas, AS Bass, J Koerner, S Matis‐Mitchell, MK Pugsley, M Skinner, ...
British journal of pharmacology 172 (16), 4002-4011, 2015
542015
Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals
HM Vargas, HR Amouzadeh, MJ Engwall
Expert opinion on drug safety 12 (1), 91-102, 2013
542013
سیستم در حال حاضر قادر به انجام عملکرد نیست. بعداً دوباره امتحان کنید.
مقاله‌ها 1–20